Clinical Trials Browser

Terminated × OTHER × regorafenib × Clear all

NCT04777851 2026-03-09

REPLACE

Phase 3 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT04327700 2026-03-05

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Phase 2 Terminated

2 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

GastrointestinalOther solid neoplasm

MSI-H Colorectal Cancer

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT02581059 2024-06-26

Efficacy of Ginseng for Patients on Regorafenib

Phase 2 Terminated

10 enrolled 19 charts

Gastrointestinal

Fatigue, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02383433 2023-10-23

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Phase 2 Terminated

2 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT03722108 2023-10-16

REGIRI

Phase 1/2 Terminated

Adenocarcinoma

NCT02910843 2023-01-10

RECAP

Phase 1 Terminated

Gastrointestinal

Rectal Neoplasms

NCT03099486 2022-02-07

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Phase 2 Terminated

2 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT04476329 2021-12-30

ReDos HCC

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Phase 2 Terminated

1 enrolled 7 charts

Noonan Syndrome 6, Melanoma

NCT02402036 2019-01-29

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

Phase 2 Terminated

10 enrolled 8 charts

Gastrointestinal

Colonic Neoplasms

NCT02234180 2018-10-17

Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery

Phase 2 Terminated

3 enrolled 5 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02241720 2018-01-11

Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers

Phase 2 Terminated

5 enrolled 6 charts

Gastrointestinal

Gastrointestinal Neoplasms

NCT02278783 2017-10-06

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Phase 2 Terminated

1 enrolled 5 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02175654 2017-08-01

PREVIUM

Phase 2 Terminated

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02199223 2016-09-22

Regorafenib + Panitumumab for Colorectal Cancers

Phase 1 Terminated

Gastrointestinal

KRAS and NRAS Wild-type Colorectal Cancer